Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
about
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell responseExtracellular HSPs: The Complicated Roles of Extracellular HSPs in ImmunityThe past, present and future of immunotherapy against tumorAnti-CTLA4 monoclonal antibodies: the past and the future in clinical applicationCTLA-4 blockade in tumor models: an overview of preclinical and translational researchImmunotherapy in the treatment of non-small cell lung cancerAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookNovel immunotherapies for hematologic malignanciesImmune microenvironment in colorectal cancer: a new hallmark to change old paradigmsImmune dysregulation in human subjects with heterozygous germline mutations in CTLA4Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal.Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitroThe immune response to tumors as a tool toward immunotherapy.Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanomaA prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to comeIndirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation.Challenges and future perspectives of T cell immunotherapy in cancerIntraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells.Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare diseasePhosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.The Role of Regulatory T Cells in Mesothelioma.LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer modelImmune-based Therapy Clinical Trials in Hepatocellular CarcinomaTargeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer.Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer.Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysisEvolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC.Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesEnhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
P2860
Q24602822-511E6000-8BC3-4964-8880-CE78F533AF88Q26747413-1A988EDB-187F-47F1-9D91-E07495D530FEQ26799896-5DAFE888-D981-4CA3-98C8-40A13965B4DAQ26858779-82D87019-3F11-4DA8-A11B-0D31A649E792Q26992295-CF274BD0-EFE8-4FA2-A171-4DC632E73BB8Q27000382-3696FA20-C65F-4E65-A547-C3673B8B1706Q27004178-5A8DDBE7-4E56-4B74-9BB7-3909DCEAA738Q27004436-80E2CCBD-ADB9-413C-81F9-591814566EC6Q27008654-79BA8BFA-2C4C-4703-B073-DB46E35D1495Q28247732-5872756B-46F8-4B2C-A98C-5B1C305CA791Q30533331-10084A97-2D83-4D6E-81CC-6FDA2FD20A8CQ33607108-8C38A3B3-F7AE-49FD-A0D4-0B50D10EFFCEQ33776925-F0A691CA-44E2-4E9B-94B1-5CC5D5D5837DQ33859814-F6935E0D-CCF5-4EAE-A487-08DD9B44DFF5Q33889603-4940EF13-B088-48AE-99D4-60DB2BD32A4FQ34375163-D7207F63-F0F4-480E-91DC-34D1B64B905EQ34615021-A422014C-B2CC-4F07-BB44-725E1EB8B3A8Q34634545-B4658DF0-42DB-4801-98FB-7F06B80A0E53Q34651347-F1707A04-A987-4611-95E7-B8F9AE63320BQ35580479-EEDDC99E-1320-4EAC-AFDE-E20195A51FB5Q35614792-7B40C4F7-4B89-4BE3-A77F-C191553BC6C5Q35617517-EC0BD33D-21ED-46C5-8F29-E471A8757513Q35624884-FB094A82-C5F0-46D3-A738-C9158D98C8BFQ35786957-50381C55-C50F-47F0-BE5D-7701E92BA1F3Q35843507-80C413E3-BC9F-448B-8E4D-E3205794C70AQ35876847-2BF8E613-2F0D-400E-B128-C4F7C2F4B9C2Q35913194-DBB46B85-C10D-47D7-83FC-54781C966CCCQ36054460-F70CF5E3-9B39-44C4-8FC3-39771E3B6358Q36057482-8D6361DA-4A51-4DCE-A0BD-970BF89422BCQ36101238-CD5031DF-A1D6-48BE-8835-3E57829EDDBCQ36413772-1AEB0038-2049-4925-8D01-2E821306341EQ36571270-6255C5E2-B097-432D-98BE-37F34C5D5242Q36620552-72A8F73D-AF36-47FA-BEBB-2810ED7CF5A4Q36711007-101A5AA1-123D-4C64-8A0D-8EA48F0A797AQ36827259-78A5CA23-88B6-4BFB-A4B8-387056ED3EDEQ36975877-9FF2836E-F18D-4D93-8CE9-6940E0D75DC5Q37007501-A5323574-0C5A-470F-BF31-1A2880BC0E97Q37058110-E43332BA-8CDE-4C05-8DF1-42DFE866572AQ37137360-0FE61401-10B1-47F8-9B76-4CABBB62FB79Q37139813-EBD5FFFD-3E7C-4740-AEFF-AA250D8476C4
P2860
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-CTLA-4 antibody therapy: ...... ment of a novel immunotherapy.
@en
Anti-CTLA-4 antibody therapy: ...... ment of a novel immunotherapy.
@nl
type
label
Anti-CTLA-4 antibody therapy: ...... ment of a novel immunotherapy.
@en
Anti-CTLA-4 antibody therapy: ...... ment of a novel immunotherapy.
@nl
prefLabel
Anti-CTLA-4 antibody therapy: ...... ment of a novel immunotherapy.
@en
Anti-CTLA-4 antibody therapy: ...... ment of a novel immunotherapy.
@nl
P2860
P1433
P1476
Anti-CTLA-4 antibody therapy: ...... ment of a novel immunotherapy.
@en
P2093
Jedd D Wolchok
Margaret K Callahan
P2860
P304
P356
10.1053/J.SEMINONCOL.2010.09.001
P577
2010-10-01T00:00:00Z